Business Context and Reporting Period
This Form 8-K Current Report was filed by Altimmune, Inc. on November 12, 2024, covering events occurring on November 11, 2024. The filing primarily addresses a significant change in executive leadership within the finance function.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment details.
Material Changes
- Appointment of CFO: The Board of Directors appointed Gregory Weaver as Chief Financial Officer (CFO), effective November 11, 2024. He serves as the principal accounting and financial officer.
- Transition of Interim CFO: Andrew Shutterly transitioned from Interim CFO to Corporate Controller on November 11, 2024, and is no longer the principal financial or accounting officer.
- Compensation Package: Mr. Weaver's employment agreement includes:
- Annual base salary of $475,000.
- Target annual bonus of 40% of base salary.
- Sign-on equity grant of 225,000 stock options (25% vesting in one year, remainder over 36 months).
- Equity grant of 75,000 restricted stock units (25% vesting in one year, remainder over three years).
- Severance Provisions: In the event of termination without Cause or resignation for Good Reason, Mr. Weaver is entitled to 12 months of salary and COBRA coverage. In the event of a Change in Control followed by such termination within 12 months, he is entitled to 12 months of salary plus the target bonus, COBRA coverage, and full acceleration of unvested equity.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of operational risks. It is a disclosure of a specific corporate governance event and the associated compensatory arrangements.
Investor Verification Checklist
- Verify the full text of the Employment Agreement (Exhibit 10.1) for specific performance metrics tied to the bonus.
- Confirm the vesting schedule details and any potential acceleration clauses beyond the Change in Control scenario.
- Review the press release (Exhibit 99.1) for any additional context regarding the strategic rationale for the leadership change.
- Monitor future filings for the impact of this leadership change on the company's financial reporting and strategic direction.